Laboratory Corporation of America Holdings — Cyborg Score 8/10
Strong
Clinical Laboratory Services & Diagnostics
Strategic Profile
The company offers various tests including blood chemistry analyses, urinalyses, blood cell counts, thyroid, PAP, hemoglobin A1C, prostate-specific antigens, sexually transmitted diseases, and substance-abuse tests. It serves pharmaceutical, biotechnology, medical device companies, MCOs, employer plans, health insurance providers, hospitals, healthcare providers, and patients.
Cyborg Score Rationale
Earnings were up 78.47% in 2024, and ten research analysts rated the stock as Buy with only three Hold ratings, and consensus price target of $300.75 represents upside potential. Strong analyst sentiment and earnings momentum support positive outlook.
Top Insights
TTM revenue of $13.76 billion with 2024 revenue of $13.00 billion, up 6.97% year-over-year
Trailing P/E of 24.70 and forward P/E of 14.20 with 6.21% profit margin
Market cap of $22.72 billion has increased 10.40% in one year
Q3 2025 benefited from strong demand for diagnostic tests with guidance raised for full year
Named Competitors
Quest Diagnostics — Clinical laboratory diagnostics and drug development services
Sonic Healthcare — Pathology and laboratory medicine services
Charles River Laboratories — Drug development and laboratory services for pharmaceuticals
Recent Developments
(February 2026) Announced availability of Elecsys pTau-181 test
(February 2026) Extended receivables facility to enhance liquidity flexibility
(February 2026) JPMorgan raised price target from $317 to $319
(January 2026) Weiss Ratings upgraded from hold to buy rating
Open the full interactive Laboratory Corporation of America Holdings report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.